Skip to main content
Premium Trial:

Request an Annual Quote

Plexera Inks Option for Protein Array Technology from Harvard Spinout

NEW YORK (GenomeWeb News) – Lumera’s life sciences subsidiary Plexera today said it has signed an option agreement for protein array technology from Harvard University spinout Auguron Biosciences.
 
The company said it will use Auguron’s Nucleic Acid Programmable Protein Array (NAPPA), which was developed at the Harvard Institute of Proteomics, to generate functional proteins on high density microchips from surface printed DNA.
 
The deal builds on a longstanding collaboration between Lumera and the Harvard Institute of Proteomics related to the NAPPA technology. Auguron was formed early last year to commercialize technology developed in the institute.
 
The option agreement grants Plexera access for one year and includes the potential for another one-year extension. During that period, Plexera said it will test and develop the NAPPA technology as a potential content source for its Plexera Kx Array platform in collaboration with Auguron and with other partners, which the company did not name.
 
The agreement also gives Plexera the option to negotiate an exclusive license for NAPPA.
 
"By printing DNA and expressing proteins in-situ, NAPPA skips the expense, time, yield and activity consuming steps associated with conventional printed protein arrays,” Auguron CEO Jim Richey said in a statement.
 
Financial terms of the license were not disclosed.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.